[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100454226":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":20,"locations":26,"responsibleParty":45,"collaborators":48,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":7,"enrollmentInfo":66,"targetDuration":7,"studyType":69,"phases":7,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University of Tasmania","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Cognitive test scores, clinical diagnosis and blood biomarkers","Clinical diagnosis of Alzheimer's disease, mild cognitive impairment or normal ageing.\n\nCognitive test score on CANTAB Blood biomarker (p-tau 181) level",[14,17],{"name":15,"affiliation":5,"role":16},"Prof Vickers, PhD DSc","STUDY_DIRECTOR",{"name":18,"affiliation":5,"role":19},"A\u002FProf Bai, PhD MSc","PRINCIPAL_INVESTIGATOR",[21],{"name":22,"role":23,"phone":24,"phoneExt":7,"email":25},"A\u002FProf Alty, MD FRACP","CONTACT","+61 (0)3 36226 4273","Jane.Alty@utas.edu.au",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Hobart","Tasmania","7001","Australia","AU",{"type":35,"coordinates":36},"Point",[37,38],147.32941,-42.87936,{"lat":38,"lon":37},[41,42],{"name":22,"role":23,"phone":24,"phoneExt":7,"email":25},{"name":15,"role":23,"phone":43,"phoneExt":7,"email":44},"+61 3 6226 4808","James.Vickers@utas.edu.au",{"type":19,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Jane Alty","Associate Professor of Neurology",[49,51,53],{"name":50,"class":6},"National Health and Medical Research Council, Australia",{"name":52,"class":6},"University of Sydney",{"name":54,"class":6},"University of Leeds","100454226","tas-test-online-motor-cognitive-tests-for-early-detection-of-alzheimers-disease-100454226",false,"NCT05194787","TAS Test: Online Motor-cognitive Tests for Early Detection of Alzheimer's Disease","TAS Test: Determining the Feasibility and Validity of Online Motor-cognitive Testing for Early Detection of Alzheimer's Disease","TASTest","Inclusion Criteria: \\> 50years old\n\nExclusion Criteria: established diagnosis of dementia",true,"ALL","50 Years",{"count":67,"type":68},3000,"ESTIMATED","OBSERVATIONAL","Global dementia prevalence is rising. Alzheimer's disease (AD), the most common cause, has devastating effects on people's quality of life. AD has a preclinical (pre-AD) period of 10-20 years when brain pathology silently progresses before any cognitive symptoms appear. Current tests for pre-AD are invasive, costly and unsuitable for screening at population level. Similar to screening for pre-diabetes and carcinoma in situ, it is important to detect AD at the preclinical stage in order to offer early interventions before the pathology progresses to the irrerversible degenerative stage. In the study, research will develop a new scalable test (TAS Test) by combining two innovative ideas: hand-movement tests to detect pre-AD \\>10 years before cognitive symptoms begin; and computer vision so people can \"self-test\" online using home computers. This unique approach builds on recent discoveries that hand-movement patterns change in pre-AD. The research team will use exquisitely precise computer vision methods to automatically analyse movement data from thousands of participants, and combine this with machine learning of overall motor-cognitive performance. The project team has access to 3 well-phenotyped cohorts, \\>10,000 existing participants and a cutting-edge assay for a blood AD biomarker, ptau181. The research team will develop a TAS Test algorithm to classify hand-movement and cognitive test data for pre-AD risk (p-taua181 levels) and determine TAS Test's precision to prospectively predict 5-year risks of cognitive decline and AD.",[72,73,74],"Alzheimer Disease","Dementia","Age-related Cognitive Decline",[76,77,78,79],"pre-clinical","early detection","online tests","Artificial intelligence","2023-10-27",{"date":82,"type":83},"2023-10-30","ACTUAL",{"date":85,"type":83},"2021-03-05",{"date":87,"type":68},"2030-12",{"name":5,"class":6},1]